Literature DB >> 24027196

Androgen receptor signaling regulates DNA repair in prostate cancers.

William R Polkinghorn1, Joel S Parker, Man X Lee, Elizabeth M Kass, Daniel E Spratt, Phillip J Iaquinta, Vivek K Arora, Wei-Feng Yen, Ling Cai, Deyou Zheng, Brett S Carver, Yu Chen, Philip A Watson, Neel P Shah, Sho Fujisawa, Alexander G Goglia, Anuradha Gopalan, Haley Hieronymus, John Wongvipat, Peter T Scardino, Michael J Zelefsky, Maria Jasin, Jayanta Chaudhuri, Simon N Powell, Charles L Sawyers.   

Abstract

UNLABELLED: We demonstrate that the androgen receptor (AR) regulates a transcriptional program of DNA repair genes that promotes prostate cancer radioresistance, providing a potential mechanism by which androgen deprivation therapy synergizes with ionizing radiation. Using a model of castration-resistant prostate cancer, we show that second-generation antiandrogen therapy results in downregulation of DNA repair genes. Next, we demonstrate that primary prostate cancers display a significant spectrum of AR transcriptional output, which correlates with expression of a set of DNA repair genes. Using RNA-seq and ChIP-seq, we define which of these DNA repair genes are both induced by androgen and represent direct AR targets. We establish that prostate cancer cells treated with ionizing radiation plus androgen demonstrate enhanced DNA repair and decreased DNA damage and furthermore that antiandrogen treatment causes increased DNA damage and decreased clonogenic survival. Finally, we demonstrate that antiandrogen treatment results in decreased classical nonhomologous end-joining. SIGNIFICANCE: We demonstrate that the AR regulates a network of DNA repair genes, providing a potential mechanism by which androgen deprivation synergizes with radiotherapy for prostate cancer. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24027196      PMCID: PMC3888815          DOI: 10.1158/2159-8290.CD-13-0172

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  27 in total

1.  XRCC3 promotes homology-directed repair of DNA damage in mammalian cells.

Authors:  A J Pierce; R D Johnson; L H Thompson; M Jasin
Journal:  Genes Dev       Date:  1999-10-15       Impact factor: 11.361

2.  ARN-509: a novel antiandrogen for prostate cancer treatment.

Authors:  Nicola J Clegg; John Wongvipat; James D Joseph; Chris Tran; Samedy Ouk; Anna Dilhas; Yu Chen; Kate Grillot; Eric D Bischoff; Ling Cai; Anna Aparicio; Steven Dorow; Vivek Arora; Gang Shao; Jing Qian; Hong Zhao; Guangbin Yang; Chunyan Cao; John Sensintaffar; Teresa Wasielewska; Mark R Herbert; Celine Bonnefous; Beatrice Darimont; Howard I Scher; Peter Smith-Jones; Mark Klang; Nicholas D Smith; Elisa De Stanchina; Nian Wu; Ouathek Ouerfelli; Peter J Rix; Richard A Heyman; Michael E Jung; Charles L Sawyers; Jeffrey H Hager
Journal:  Cancer Res       Date:  2012-01-20       Impact factor: 12.701

3.  Abiraterone and increased survival in metastatic prostate cancer.

Authors:  Johann S de Bono; Christopher J Logothetis; Arturo Molina; Karim Fizazi; Scott North; Luis Chu; Kim N Chi; Robert J Jones; Oscar B Goodman; Fred Saad; John N Staffurth; Paul Mainwaring; Stephen Harland; Thomas W Flaig; Thomas E Hutson; Tina Cheng; Helen Patterson; John D Hainsworth; Charles J Ryan; Cora N Sternberg; Susan L Ellard; Aude Fléchon; Mansoor Saleh; Mark Scholz; Eleni Efstathiou; Andrea Zivi; Diletta Bianchini; Yohann Loriot; Nicole Chieffo; Thian Kheoh; Christopher M Haqq; Howard I Scher
Journal:  N Engl J Med       Date:  2011-05-26       Impact factor: 91.245

4.  Integrative genomic profiling of human prostate cancer.

Authors:  Barry S Taylor; Nikolaus Schultz; Haley Hieronymus; Anuradha Gopalan; Yonghong Xiao; Brett S Carver; Vivek K Arora; Poorvi Kaushik; Ethan Cerami; Boris Reva; Yevgeniy Antipin; Nicholas Mitsiades; Thomas Landers; Igor Dolgalev; John E Major; Manda Wilson; Nicholas D Socci; Alex E Lash; Adriana Heguy; James A Eastham; Howard I Scher; Victor E Reuter; Peter T Scardino; Chris Sander; Charles L Sawyers; William L Gerald
Journal:  Cancer Cell       Date:  2010-06-24       Impact factor: 31.743

5.  Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.

Authors:  M Bolla; D Gonzalez; P Warde; J B Dubois; R O Mirimanoff; G Storme; J Bernier; A Kuten; C Sternberg; T Gil; L Collette; M Pierart
Journal:  N Engl J Med       Date:  1997-07-31       Impact factor: 91.245

6.  Lack of prostate cancer radiosensitization by androgen deprivation.

Authors:  A Pollack; N Salem; F Ashoori; P Hachem; M Sangha; A C von Eschenbach; M L Meistrich
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-11-15       Impact factor: 7.038

7.  Genetic steps of mammalian homologous repair with distinct mutagenic consequences.

Authors:  Jeremy M Stark; Andrew J Pierce; Jin Oh; Albert Pastink; Maria Jasin
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

8.  Castration therapy results in decreased Ku70 levels in prostate cancer.

Authors:  Firas L T Al-Ubaidi; Niklas Schultz; Olga Loseva; Lars Egevad; Torvald Granfors; Thomas Helleday
Journal:  Clin Cancer Res       Date:  2013-01-24       Impact factor: 12.531

9.  The mutational landscape of lethal castration-resistant prostate cancer.

Authors:  Catherine S Grasso; Yi-Mi Wu; Dan R Robinson; Xuhong Cao; Saravana M Dhanasekaran; Amjad P Khan; Michael J Quist; Xiaojun Jing; Robert J Lonigro; J Chad Brenner; Irfan A Asangani; Bushra Ateeq; Sang Y Chun; Javed Siddiqui; Lee Sam; Matt Anstett; Rohit Mehra; John R Prensner; Nallasivam Palanisamy; Gregory A Ryslik; Fabio Vandin; Benjamin J Raphael; Lakshmi P Kunju; Daniel R Rhodes; Kenneth J Pienta; Arul M Chinnaiyan; Scott A Tomlins
Journal:  Nature       Date:  2012-07-12       Impact factor: 49.962

10.  Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.

Authors:  Brett S Carver; Caren Chapinski; John Wongvipat; Haley Hieronymus; Yu Chen; Sarat Chandarlapaty; Vivek K Arora; Carl Le; Jason Koutcher; Howard Scher; Peter T Scardino; Neal Rosen; Charles L Sawyers
Journal:  Cancer Cell       Date:  2011-05-17       Impact factor: 31.743

View more
  177 in total

1.  Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts.

Authors:  Hung-Ming Lam; Holly M Nguyen; Mark P Labrecque; Lisha G Brown; Ilsa M Coleman; Roman Gulati; Bryce Lakely; Daniel Sondheim; Payel Chatterjee; Brett T Marck; Alvin M Matsumoto; Elahe A Mostaghel; Michael T Schweizer; Peter S Nelson; Eva Corey
Journal:  Eur Urol       Date:  2019-06-19       Impact factor: 20.096

Review 2.  Profiles of Radioresistance Mechanisms in Prostate Cancer.

Authors:  Luksana Chaiswing; Heidi L Weiss; Rani D Jayswal; Daret K St Clair; Natasha Kyprianou
Journal:  Crit Rev Oncog       Date:  2018

Review 3.  Pharmacological methods to transcriptionally modulate double-strand break DNA repair.

Authors:  Alanna R Kaplan; Peter M Glazer
Journal:  Int Rev Cell Mol Biol       Date:  2019-12-18       Impact factor: 6.813

4.  Potential Impact of 68Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer.

Authors:  Jeremie Calais; Amar U Kishan; Minsong Cao; Wolfgang P Fendler; Matthias Eiber; Ken Herrmann; Francesco Ceci; Robert E Reiter; Matthew B Rettig; John V Hegde; Narek Shaverdian; Chris R King; Michael L Steinberg; Johannes Czernin; Nicholas G Nickols
Journal:  J Nucl Med       Date:  2018-04-13       Impact factor: 10.057

Review 5.  An arranged marriage for precision medicine: hypoxia and genomic assays in localized prostate cancer radiotherapy.

Authors:  R G Bristow; A Berlin; A Dal Pra
Journal:  Br J Radiol       Date:  2014-02-03       Impact factor: 3.039

6.  Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage.

Authors:  Daniel E Spratt; Hebert A Vargas; Zachary S Zumsteg; Jennifer S Golia Pernicka; Joseph R Osborne; Xin Pei; Michael J Zelefsky
Journal:  Eur Urol       Date:  2016-08-11       Impact factor: 20.096

Review 7.  Roles for MDC1 in cancer development and treatment.

Authors:  Sophie E Ruff; Susan K Logan; Michael J Garabedian; Tony T Huang
Journal:  DNA Repair (Amst)       Date:  2020-08-11

Review 8.  The convergence of DNA damage checkpoint pathways and androgen receptor signaling in prostate cancer.

Authors:  Huy Q Ta; Daniel Gioeli
Journal:  Endocr Relat Cancer       Date:  2014-08-05       Impact factor: 5.678

9.  miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and Src.

Authors:  Xu-Bao Shi; Ai-Hong Ma; Lingru Xue; Meimei Li; Hao G Nguyen; Joy C Yang; Clifford G Tepper; Regina Gandour-Edwards; Christopher P Evans; Hsing-Jien Kung; Ralph W deVere White
Journal:  Cancer Res       Date:  2015-11-16       Impact factor: 12.701

10.  Checkpoint Kinase 2 Negatively Regulates Androgen Sensitivity and Prostate Cancer Cell Growth.

Authors:  Huy Q Ta; Melissa L Ivey; Henry F Frierson; Mark R Conaway; Jaroslaw Dziegielewski; James M Larner; Daniel Gioeli
Journal:  Cancer Res       Date:  2015-11-16       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.